Activation of two distinct MAPK pathways governs constitutive expression of matrix metalloproteinase-1 in human pancreatic cancer cell lines

被引:33
作者
Endo, Hitoshi [1 ]
Watanabe, Tetsu [1 ]
Sugioka, Yoshihiko [1 ]
Niioka, Maki [2 ]
Inagaki, Yutaka [1 ]
Okazaki, Isao [1 ,3 ]
机构
[1] Tokai Univ, Sch Med, Dept Community Hlth, Isehara, Kanagawa 2591193, Japan
[2] Tokai Univ, Sch Med, Teaching & Res Support Ctr, Isehara, Kanagawa 2591193, Japan
[3] Int Univ Hlth & Welf, Dept Internal Med, Sanno Hosp, Minato Ku, Tokyo 1070052, Japan
关键词
pancreatic cancer; matrix metalloproteinase-1; activator protein-1; extracellular signal-regulated kinases; c-Jun NH2-terminal kinases; C-JUN; PROTEIN-KINASES; GENE-EXPRESSION; COLLAGENASE-1; MMP-1; MELANOMA-CELLS; MURINE MODEL; CARCINOMA; INHIBITION; PROGRESSION; METASTASIS;
D O I
10.3892/ijo_00000440
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
Elevated matrix metalloproteinase-1 (MMP-1) expression is known to correlate with poor prognosis of pancreatic cancer. We investigated the molecular mechanisms of constitutive expression of MMP-1 in pancreatic cancer cell lines. Expression of MMP-1 mRNA and protein as well as its enzymatic activity were observed in three pancreatic cancer cell lines. Transient transfection assays of two MMP-1 promoter/luciferase constructs (full-length 4.4-kb or proximal 0.6-kb region) showed high levels of transcription in pancreatic cancer cells compared with non-MMP-1 producing cells. The 0.6-kb promoter region of MMP-1 gene contained three activator proteni-1 (AP-1) sites and the strong AP-1 activity was detected by electrophoretic mobility shift assays (EMSAs). In these cells, production and phosphorylation of c-Jun were commonly observed. Phosphorylated C-Jun NH2-terminal kinase (p-JNK) and activator transcription factor-2 (p-ATF-2) were also detected in two of the three cell lines. Phosphorylated extracellular signal-regulated kinase (p-ERK) was observed in one. The promoter activity, AP-1-binding activity and MMP-1 production were suppressed by a specific inhibitor of JNK or MEK. K-ras mutation, reported to be present in three cell lines used, is known to activate JNK and ERK pathways. Considering the facts together, our results revealed that activation of JNK/AP-1 or ERK/AP-1 pathway plays crucial roles in constitutive transactivation of MMP-1 in these cancer cells. This study contributes to provide new insights into strategies for inhibiting tumor cell invasion in pancreatic cancer.
引用
收藏
页码:1237 / 1245
页数:9
相关论文
共 50 条
[1]
Pancreatic cancer biology and genetics [J].
Bardeesy, N ;
DePinho, RA .
NATURE REVIEWS CANCER, 2002, 2 (12) :897-909
[2]
COMPARATIVE-ANALYSIS OF MUTATIONS IN THE P53 AND K-RAS GENES IN PANCREATIC-CANCER [J].
BERROZPE, G ;
SCHAEFFER, J ;
PEINADO, MA ;
REAL, FX ;
PERUCHO, M .
INTERNATIONAL JOURNAL OF CANCER, 1994, 58 (02) :185-191
[3]
Matrix metalloproteinases and their role in pancreatic cancer: A review of preclinical studies and clinical trials [J].
Bloomston, M ;
Zervos, EE ;
Rosemurgy, AS .
ANNALS OF SURGICAL ONCOLOGY, 2002, 9 (07) :668-674
[4]
A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer [J].
Bramhall, SR ;
Schulz, J ;
Nemunaitis, J ;
Brown, PD ;
Baillet, M ;
Buckels, JAC .
BRITISH JOURNAL OF CANCER, 2002, 87 (02) :161-167
[5]
Marimastat as first-line therapy for patients with unresectable pancreatic cancer: A randomized trial [J].
Bramhall, SR ;
Rosemurgy, A ;
Brown, PD ;
Bowry, C ;
Buckels, JAC .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (15) :3447-3455
[6]
Chang FM, 2003, INT J ONCOL, V22, P469
[7]
CHEN WH, 1982, IN VITRO CELL DEV B, V18, P24
[8]
Serine/threonine protein kinases and apoptosis [J].
Cross, TG ;
Scheel-Toellner, D ;
Henriquez, NV ;
Deacon, E ;
Salmon, M ;
Lord, JM .
EXPERIMENTAL CELL RESEARCH, 2000, 256 (01) :34-41
[9]
Matrix metalloproteinases (MMP), EMMPRIN (extracellular matrix metalloproteinase inducer) and mitogen-activated protein kinases (MAPK): Co-expression in metastatic serous ovarian carcinoma [J].
Davidson, B ;
Givant-Horwitz, V ;
Lazarovici, P ;
Risberg, B ;
Nesland, JM ;
Trope, CG ;
Schaefer, E ;
Reich, R .
CLINICAL & EXPERIMENTAL METASTASIS, 2003, 20 (07) :621-631